Objective To investigate the clinical characteristics of Landau-Kleffner syndrome.Methods The clinical data of 3 patients with Landau-Kleffner syndrome was analyzed retrospectively.Results The clinical features of 3 cases presented acquired aphasia,epileptic attack and psychical behaviour abnormality.The EEG showed foci spike wave discharge,while the CT and MRI examination were normal.The epileptic attacks were controlled after treatment,but the recovery of aphasia and psychical behaviour abnormality was poor.Conclusions Acquired aphasia and epileptic attack are the clinical characteristics of Landau-Kleffner syndrome.The EEG shows spike wave dischargeis.Partial recovery can be obtained post-treatment.

Objective To investigate the clinical features of limbic epilepsies and limbic status epilepticus.Methods The clinical data of two patients with limbic epilepsies and one patient with limbic status epilepticus were analysed retrospectively.Results 2 patients with limbic epilepsia were all young-aged onset of the disease.They manifested bouts of unconsciousness,nervous and fear,various automatism and autonomic nerves symptom.EEG showed spike discharge in unilateral or bilateral temporal area.MRI showed left hippocampns sclerosis in one case.Another case presented calcification focus in right internal temporal.One patient with limbic status epilepticus was middle-aged male,he manifested repeatedly onset of unconscious insanity,behavior disorders and psychiatric symptoms.There was over 30 min for once onset.EEG showed ? wave or ? wave in bilateral frontal and temporal area.MRI showed arachnoid cyst in left temporal lobe anterior.Three cases were controlled by Carbamazepine or Oxcarbazepine.Conclusion The clinical feature of limbic epilepsies and limbic status epilepticus have bouts of automatism,automic nerve symptom and psychiatric symptom attact,which have relation to impairment of hippocampus and almond body in interal temporal.

Objective To investigate the efficacy of continuous hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen and its multimodality therapeutic regimen in the treatment of patients with advanced hepatocellular carcinoma, as well as the influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 66 patients with advanced hepatocellular carcinoma who received continuous HAIC with FOLFOX regimen in Nanfang Hospital, Southern Medical University, from September 2018 to November 2021. The patients were observed in terms of objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) after treatment, and treatment-related adverse reactions were recorded. For the patients with portal vein tumor thrombus, the effect of the treatment on portal vein tumor thrombus was assessed. The Kaplan-Meier method was used for survival analysis, and the Cox regression analysis was used to investigate the influencing factors for prognosis. Results According to the RECIST1.1 criteria, FOLFOX-HAIC and its multimodality therapeutic regimen achieved an ORR of 33.3% (22/66) and a DCR of 86.4% (57/66) in the treatment of 66 patients with advanced hepatocellular carcinoma, with an mPFS time of 8.2 months and an mOS time of 22.1 months. Among the 39 patients with portal vein tumor thrombus, 2 achieved complete remission, 8 achieved partial remission, 24 achieved stable disease, and 5 had disease progression, with an ORR of 25.6% (10/39) and a DCR of 87.2% (34/39). The main adverse reactions included gastrointestinal reactions (16.7%, 11/66), pyrexia (12.1%, 8/66), liver area pain (10.6%, 7/66), bone marrow suppression (3.0%, 2/66), and contrast agent allergy (3.0%, 2/66), and there were no grade > Ⅳ toxic or side effects or deaths caused by such complications. The Cox regression analysis showed that extrahepatic metastasis (hazard ratio [ HR ]=2.668, 95% confidence interval [ CI ]: 1.357-5.245, P < 0.05) and prothrombin time (PT) ( HR =1.282, 95% CI : 1.080-1.630, P < 0.05) were independent risk factors for PFS, and aspartate aminotransferase level ( HR =1.008, 95% CI : 1.002-1.013, P < 0.05) and PT ( HR =1.303, 95% CI : 1.046-1.630, P < 0.05) were independent risk factors for OS. Conclusion FOLFOX-HAIC and its multimodality therapeutic regimen has a certain clinical effect with controllable adverse reactions in the treatment of advanced hepatocellular carcinoma.